PTCT insider uses 10b5-1 plan to exercise and sell 24,921 shares
Rhea-AI Filing Summary
PTC Therapeutics insider transactions: an executive exercised stock options and sold an equal number of shares under a pre-existing trading plan. On 10/03/2025 and 10/06/2025, the reporting person exercised stock options with an exercise price of $39.42 and acquired 24,921 shares in aggregate. The filing shows sales of 24,921 shares executed at weighted average prices ranging roughly from $64.00 to $67.29, producing reported sale prices such as $64.43, $65.47, and $66.44. Following these transactions the reporting person beneficially owns 103,901 shares.
The filing notes the trades were effected pursuant to a written Rule 10b5-1 plan adopted on 12/05/2024, and that the underlying options were originally granted on 01/05/2023 with a vesting schedule that began on 01/05/2024. The pattern—exercise at $39.42 and near-immediate sales at ~$64–$67—is consistent with option exercises followed by planned sales, leaving the reporting person with 103,901 shares after the reported activity.
Positive
- Trades executed under a documented Rule 10b5-1 plan adopted on 12/05/2024
- Options exercised at a $39.42 strike, demonstrating liquidity conversion of vested compensation
- Final beneficial ownership disclosed as 103,901 shares, maintaining transparent post-trade holdings
Negative
- Aggregate sales of 24,921 shares reduced the reporting person's holdings
- Immediate sales after exercise realize gains but decrease insider equity exposure
Insights
Options exercised and sales executed under a 10b5-1 plan, maintaining disclosure compliance.
The reporting person exercised multiple stock options with a $39.42 strike and acquired 24,921 shares across 10/03/2025–10/06/2025. The filer checked the box indicating these trades were made pursuant to a Rule 10b5-1 plan adopted on 12/05/2024, which provides an affirmative defense for pre-arranged trading.
This structure reduces insider timing concerns by documenting pre-authorization, but investors should note the overall beneficial holding fell to 103,901 shares immediately after the activity; watch for future Form 4s or plan termination notices for changes.
Equal shares acquired and sold: 24,921 shares exercised then sold at weighted averages near $64–$67.
The filings list sales totaling 24,921 shares executed at reported weighted-average sale prices with ranges disclosed between $64.00 and $67.29. The option exercise price was $39.42, creating a per-share spread realized by the sales.
This indicates a sell-to-cover or monetization of vested options on 10/03/2025–10/06/2025. Market impact is likely limited given the modest share counts relative to typical public float, but monitor volume and any additional planned sales within the 10b5-1 schedule over the next quarter.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 2,266 | $0.00 | -- |
| Exercise | Common Stock | 2,266 | $39.42 | $89K |
| Sale | Common Stock | 2,266 | $65.07 | $147K |
| Exercise | Stock Option (Right to Buy) | 18,124 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 2,266 | $0.00 | -- |
| Exercise | Stock Option (Right to Buy) | 2,265 | $0.00 | -- |
| Exercise | Common Stock | 18,124 | $39.42 | $714K |
| Sale | Common Stock | 3,100 | $64.43 | $200K |
| Sale | Common Stock | 6,124 | $65.47 | $401K |
| Sale | Common Stock | 7,400 | $66.44 | $492K |
| Sale | Common Stock | 1,500 | $67.15 | $101K |
| Exercise | Common Stock | 2,266 | $39.42 | $89K |
| Sale | Common Stock | 536 | $64.43 | $35K |
| Sale | Common Stock | 824 | $65.73 | $54K |
| Sale | Common Stock | 906 | $66.63 | $60K |
| Exercise | Common Stock | 2,265 | $39.42 | $89K |
| Sale | Common Stock | 550 | $64.44 | $35K |
| Sale | Common Stock | 838 | $65.72 | $55K |
| Sale | Common Stock | 877 | $66.67 | $58K |
Footnotes (1)
- This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.00 to $65.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.00 to $66.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.00 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.26 to $66.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.72 to $65.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
